Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

417 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Parathyroid hormone pulsatility: physiological and clinical aspects.
Chiavistelli S, Giustina A, Mazziotti G. Chiavistelli S, et al. Bone Res. 2015 Jan 27;3:14049. doi: 10.1038/boneres.2014.49. eCollection 2015. Bone Res. 2015. PMID: 26273533 Free PMC article. Review.
Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients.
Mormando M, Chiloiro S, Bianchi A, Giampietro A, Angelini F, Tartaglione L, Nasto L, Milardi D, Formenti AM, Giustina A, De Marinis L. Mormando M, et al. Clin Endocrinol (Oxf). 2016 Nov;85(5):717-724. doi: 10.1111/cen.13161. Epub 2016 Aug 22. Clin Endocrinol (Oxf). 2016. PMID: 27437620
Two GH receptor isoforms (GHRi) have been identified: they differ for the presence/absence of a protein fragment encoded by exon 3 of GHR gene. ...This polymorphism confers a higher sensitivity to endogenous GH and to recombinant human GH (rhGH); its effect on bone …
Two GH receptor isoforms (GHRi) have been identified: they differ for the presence/absence of a protein fragment encoded by exon 3 of …
MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects.
Mazziotti G, Formenti AM, Frara S, Roca E, Mortini P, Berruti A, Giustina A. Mazziotti G, et al. Eur J Endocrinol. 2017 Nov;177(5):R231-R248. doi: 10.1530/EJE-17-0154. Epub 2017 Jun 5. Eur J Endocrinol. 2017. PMID: 28583942 Review.
The effects of long-term replacement therapy of adrenal insufficiency (AI) are still a matter of controversy. In fact, the established glucocorticoid replacement regimens do not completely reproduce the endogenous hormonal production and the monitoring of AI treatment may …
The effects of long-term replacement therapy of adrenal insufficiency (AI) are still a matter of controversy. In fact, the establishe …
Glucocorticoid-induced osteoporosis and parathyroid hormone.
Carpinteri R, Porcelli T, Mejia C, Patelli I, Bilezikian JP, Canalis E, Angeli A, Giustina A, Mazziotti G. Carpinteri R, et al. J Endocrinol Invest. 2010;33(7 Suppl):16-21. J Endocrinol Invest. 2010. PMID: 20938221 Free PMC article. Review.
PTH, when administered intermittently and at low doses, has effects on bone formation opposite to those of glucocorticoids and therefore is conceptually a more attractive approach. ...
PTH, when administered intermittently and at low doses, has effects on bone formation opposite to those of glucocorticoids and therefore is …
Growth, insulin-like growth factor I (IGF-I), and IGF-binding proteins 1 and 3 in children with severe liver disease before and after liver transplantation: a longitudinal and cross-sectional study.
Buzi F, Bontempelli AM, Alberti D, Jones J, Pilotta A, Lombardi A, Giustina A, Preece MA. Buzi F, et al. Pediatr Res. 1998 Apr;43(4 Pt 1):478-83. doi: 10.1203/00006450-199804000-00007. Pediatr Res. 1998. PMID: 9545001 Clinical Trial.
A longitudinal study (LS) involved 17 infants (9 male) aged 0.73-2.38 y at LT; mean (+/- SD) height (Ht) SD score (SDS) at LT was -2.02 (+/- 1.25). In a cross-sectional study, there were 123 children (73 male) aged 0.16-14.88 y (mean 3.72 y). IGF-I and IGF binding p
A longitudinal study (LS) involved 17 infants (9 male) aged 0.73-2.38 y at LT; mean (+/- SD) height (Ht) SD score (SDS) at LT was -2.
Effects of metoclopramide on the paradoxical growth hormone response to galanin in acromegaly.
Giustina A, Doga M, Bodini C, Bossoni S, Bresciani E, Bussi AR. Giustina A, et al. Endocr Res. 1993 Dec;19(4):303-15. doi: 10.1080/07435809309026684. Endocr Res. 1993. PMID: 7508379
Dopaminergic drugs were the only previously known agents able to cause a paradoxical GH fall in acromegaly. Aim of our study was to investigate the effects of a potent central dopaminergic receptor blocker, metoclopramide (MCP), on the galanin-induced paradoxical GH …
Dopaminergic drugs were the only previously known agents able to cause a paradoxical GH fall in acromegaly. Aim of our study was to i …
Growth hormone in glucocorticoid-induced osteoporosis.
Manelli F, Carpinteri R, Bossoni S, Burattin A, Bonadonna S, Agabiti Rosei E, Giustina A. Manelli F, et al. Front Horm Res. 2002;30:174-83. doi: 10.1159/000061083. Front Horm Res. 2002. PMID: 11892265 Review. No abstract available.
Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.
Giustina A, Veldhuis JD. Giustina A, et al. Endocr Rev. 1998 Dec;19(6):717-97. doi: 10.1210/edrv.19.6.0353. Endocr Rev. 1998. PMID: 9861545 Review.
Understanding the dynamic neuroendocrine mechanisms that direct the pulsatile secretion of this fundamental growth-promoting and metabolic hormone remains a critical goal, the realization of which is challenged by the exponentially accumulating matrix of experimental and c …
Understanding the dynamic neuroendocrine mechanisms that direct the pulsatile secretion of this fundamental growth-promoting and metabolic h …
Maturation of the regulation of growth hormone secretion in young males with hypogonadotropic hypogonadism pharmacologically exposed to progressive increments in serum testosterone.
Giustina A, Scalvini T, Tassi C, Desenzani P, Poiesi C, Wehrenberg WB, Rogol AD, Veldhuis JD. Giustina A, et al. J Clin Endocrinol Metab. 1997 Apr;82(4):1210-9. doi: 10.1210/jcem.82.4.3871. J Clin Endocrinol Metab. 1997. PMID: 9100598 Clinical Trial.
We administered three incremental doses of testosterone (25-, 50-, and 100-mg im injections), each over a period of 4 weeks. Studies of overnight pulsatile GH secretion and GH responses to GHRH alone or combined with L-arginine (a functional somatostatin antagonist) …
We administered three incremental doses of testosterone (25-, 50-, and 100-mg im injections), each over a period of 4 weeks. Studies …
The pharmacological aspects of the treatment of acromegaly.
Giustina A, Zaltieri G, Negrini F, Wehrenberg WB. Giustina A, et al. Pharmacol Res. 1996 Nov-Dec;34(5-6):247-68. doi: 10.1006/phrs.1996.0095. Pharmacol Res. 1996. PMID: 9076850 Review. No abstract available.
417 results
Jump to page
Feedback